Maruthur NM, Gribble MO, Bennett WL, et al. The pharmacogenetics of type 2 diabetes: a systematic review. Diabetes Care. 2014;37(3):876–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gravel S, Chiasson JL, Gaudet D, Turgeon J, Michaud V. Effect of type 2 diabetes on CYP450 enzyme activity: protocol for a case–control Pharmacokinetic study. BMJ Open. 2018;8(2):e020922.

Article  PubMed  PubMed Central  Google Scholar 

Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005;77(1):1–16.

Article  CAS  PubMed  Google Scholar 

Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41(2):89–295.

Article  CAS  PubMed  Google Scholar 

Wang C, Zhang M, Liu D, Liu X. Association of CYP17A1 gene polymorphisms with type 2 diabetes and metabolic traits in a Chinese Han population. Front Endocrinol (Lausanne). 2018;9:323.

Article  PubMed  Google Scholar 

Darakjian LI, Aslibekyan S, Ziegler TR, et al. Inflammation, diabetes, and the regulation of cytochrome P450 enzymes: a role for pharmacogenetics? Int J Mol Sci. 2021;22(12):6386.

Google Scholar 

American Diabetes Association. The pharmacogenetics of type 2 diabetes: a systematic review. Diabetes Care. 2014;37(3):876–86.

Article  Google Scholar 

Florez JC, Jablonski KA, Taylor A, et al. The C allele of ATM rs11212617 does not associate with Metformin response in the diabetes prevention program. Diabetes Care. 2012;35(9):1864–7. https://doi.org/10.2337/dc11-2301.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kullo IJ, Jarvik GP, Biesecker LG, et al. Return of results in the genomic medicine projects of the eMERGE network. Front Genet. 2014;5:50.

Article  PubMed  PubMed Central  Google Scholar 

International Diabetes Federation. IDF Diabetes Atlas, 10th edition. Brussels, Belgium: International Diabetes Federation; 2021.

Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352(21):2211–21.

Article  CAS  PubMed  Google Scholar 

Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol. 2003;17(1):27–41.

Article  CAS  PubMed  Google Scholar 

Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C19 polymorphisms. Clin Pharmacol Ther. 2005;77(6):485–94.

Google Scholar 

Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017;102(4):688–700.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Didari E, Sarhangi N, Afshari M, Aghaei Meybodi HR, Hasanzad M. A pharmacogenetic pilot study of CYP2C9 common genetic variant and sulfonylureas therapeutic response in type 2 diabetes mellitus patients. J Diabetes Metab Disord. 2021;20(2):1513–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abdel Salam RF, Zeyada R, Osman NA. Effect of CYP2C9 gene polymorphisms on response to treatment with sulfonylureas in a cohort of Egyptian type 2 diabetes mellitus patients. Comp Clin Path. 2014;23(2):341–6.

Article  CAS  Google Scholar 

Elnazir HA, Azab SM, El-Tahlawy EM, et al. Influence of CYP2C9 gene polymorphism on sulfonylurea treatment response in Egyptian type 2 diabetic patients. Acta Diabetol. 2020;57(8):975–83.

Google Scholar 

Rezaei Z, Khalilzadeh O, Amin M, et al. Impact of CYP2C9 genetic polymorphisms on pharmacokinetics of Glibenclamide and Gliclazide in Iranian patients with type 2 diabetes. J Clin Pharm Ther. 2016;41(1):58–63.

Google Scholar 

Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41(12):913–58.

Article  CAS  PubMed  Google Scholar 

Zhang W, Tanaka Y, Yamazaki H, et al. Effects of CYP2C19 polymorphisms on glyburide pharmacokinetics in Chinese subjects. Drug Metab Pharmacokinet. 2015;30(4):293–8.

Google Scholar 

Mwenifumbo JC, Tyndale RF. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics. 2007;8(10):1385–402.

Article  CAS  PubMed  Google Scholar 

Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P III. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther. 2006;79(5):480–8.

Article  CAS  PubMed  Google Scholar 

Khan MA, Mahmood S, Baig M, et al. Association of CYP2C9*3 polymorphism with clinical response in Pakistani patients with type 2 diabetes treated with sulfonylureas. Pharmacogenomics J. 2019;19(3):259–64.

Google Scholar 

Shaik NA, Rao DK, Murthy DK, et al. Distribution of CYP2C8 and CYP2C9 amino acid substitution alleles in South Indian diabetes patients: A genotypic and computational protein phenotype study. Clin Exp Pharmacol Physiol. 2017;44(11):1171–9.

PubMed  Google Scholar 

Mahdi F, Raza ST, Rizvi S, Abbas S, Karoli R. Distribution of genetic polymorphisms in drug metabolizing gene cytochrome P450 (CYP2C83 and CYP2C92) in a North Indian type 2 diabetes population. Explor Res Hypothesis Med. 2016;1(3):42–6.

Google Scholar 

Sivadas A, Sahana S, Jolly B, et al. Landscape of pharmacogenetic variants associated with non-insulin antidiabetic drugs in the Indian population. BMJ Open Diabetes Res Care. 2024;12(2):e003769.

Article  PubMed  PubMed Central  Google Scholar